# Cagrilintide Dosage Protocol Guide: Reconstitution, Research Dosing & CagriSema Combination Research (2026)
For Research Use Only. Not for human use or clinical application.
Cagrilintide has emerged as one of the most-studied amylin analogs in obesity and metabolic research, particularly as part of the CagriSema dual-hormone combination. With 77 active supplier listings and growing demand from research institutions investigating next-generation weight management compounds, a clear dosage protocol guide is essential. This guide compiles data from published Phase 2 and Phase 3 clinical trials to outline the reconstitution process, escalating dose schedules, and combination research considerations used in formal study protocols.
---
What Is Cagrilintide?
Cagrilintide (development code AM833) is a long-acting acylated amylin analog engineered by Novo Nordisk. Unlike pramlintide — the only FDA-approved amylin analog, dosed three times daily due to its short half-life — cagrilintide's fatty-acid acylation extends its plasma half-life to approximately seven days, enabling once-weekly subcutaneous administration.
Amylin (also called islet amyloid polypeptide, IAPP) is a pancreatic hormone co-secreted with insulin in response to meals. It acts through calcitonin receptor/RAMP heterodimers (the AMYLIN1, AMYLIN2, and AMYLIN3 receptor complexes) to slow gastric emptying, suppress post-prandial glucagon release, and generate satiety signals in the area postrema and nucleus tractus solitarius of the brainstem. Cagrilintide recapitulates and prolongs these effects, acting on a neuroendocrine axis distinct from the GLP-1 pathway.
This mechanistic independence is what makes cagrilintide especially interesting as a research compound: it complements GLP-1 receptor agonists rather than overlapping with them, enabling additive or potentially synergistic effects when studied in combination.
Key pharmacological properties:
- •Receptor targets: AMYLIN1/2/3 receptors (calcitonin receptor + RAMP1/2/3)
- •Half-life: ~7 days (enabling once-weekly dosing in trials)
- •Route: Subcutaneous injection
- •Peptide class: Long-acting acylated amylin analog
- •Originator: Novo Nordisk
For a deeper exploration of cagrilintide's pharmacology, binding affinity data, and receptor selectivity profile, see the Cagrilintide Complete Research Profile.
---
Research Background: Amylin Agonism and the CagriSema Rationale
Amylin Receptor Pathway
The amylin receptor system operates through a brainstem-focused circuit. When amylin (or an analog like cagrilintide) binds to AMYLIN receptors in the area postrema, it activates downstream signaling in the nucleus tractus solitarius and eventually the hypothalamus, reducing caloric intake through meal-size reduction rather than aversion. Simultaneously, amylin agonism slows gastric emptying, blunts post-prandial glucagon secretion, and may improve insulin sensitivity through indirect mechanisms.
These effects are largely complementary to GLP-1 receptor agonism. GLP-1 primarily acts through intestinal L-cells and vagal afferents to amplify the incretin response; amylin agonism works more directly on central satiety circuits. The two pathways converge on energy homeostasis but through different anatomical and molecular routes.
CagriSema: The REDEFINE Trial Program
CagriSema is the investigational fixed-combination product pairing cagrilintide 2.4 mg with semaglutide 2.4 mg in a single once-weekly subcutaneous injection. Novo Nordisk's REDEFINE Phase 3 trial program is evaluating CagriSema across multiple populations, including obesity without diabetes (REDEFINE 1) and obesity with type 2 diabetes (REDEFINE 2).
Phase 2 data published in The Lancet (2021) demonstrated weight loss of approximately 15.6% at the highest dose combination over 20 weeks — meaningfully greater than either agent alone. Early REDEFINE 1 readouts from 2024 suggest ~25% mean body weight reduction at 68 weeks with CagriSema 2.4/2.4 mg, positioning it among the most efficacious pharmacological interventions in obesity research to date.
Researchers studying the CagriSema stack in preclinical and translational contexts must understand that the synergy reported in trials stems from distinct receptor targeting: GLP-1R agonism (semaglutide) plus amylin receptor agonism (cagrilintide), not redundant signaling through a shared pathway.
---
Reconstitution Guide
Cagrilintide is commonly supplied as a lyophilized (freeze-dried) powder in vials. Proper reconstitution is critical to compound integrity and accurate dosing.
Materials Required
- •Cagrilintide lyophilized powder vial (confirm mg content on label)
- •Bacteriostatic water for injection (BWI, 0.9% benzyl alcohol preserved)
- •1 mL or 3 mL insulin syringe (29–31 gauge, ½" needle)
- •18–21 gauge drawing needle for vial access (optional, reduces plunger friction)
- •Alcohol swabs
- •Clean, low-particulate work surface
> Note: Bacteriostatic water is preferred over sterile water for multi-dose vials because the benzyl alcohol preservative inhibits microbial growth. Use sterile water only for single-use applications.
Step-by-Step Reconstitution
1. Inspect the vial. Confirm the lyophilized cake is present and intact. Do not use vials with visible particulates, discoloration, or broken seals.
2. Swab the stopper. Wipe the rubber stopper of both the cagrilintide vial and the bacteriostatic water vial with an alcohol swab. Allow to air dry 30–60 seconds.
3. Draw bacteriostatic water. Using a clean syringe, withdraw the calculated volume of BWI (see concentration table below).
4. Inject water slowly into the peptide vial. Insert the needle at an angle and allow the water to run down the glass wall of the vial — do not inject directly onto the lyophilized powder cake, as this can cause aggregation.
5. Dissolve gently. Gently roll or swirl the vial between your palms for 30–60 seconds. Do not vortex or shake vigorously — agitation can cause peptide denaturation.
6. Inspect the solution. Reconstituted cagrilintide should be a clear, colorless-to-slightly-yellow solution with no visible particulates. Discard if cloudy or particulate matter is present.
7. Label and date the vial. Record the reconstitution date, concentration, and storage conditions.
Concentration Reference Table
| Vial Size | BWI Added | Resulting Concentration |
|---|---|---|
| 2 mg vial | 1.0 mL | 2 mg/mL (2000 mcg/mL) |
| 2 mg vial | 2.0 mL | 1 mg/mL (1000 mcg/mL) |
| 5 mg vial | 2.5 mL | 2 mg/mL (2000 mcg/mL) |
| 5 mg vial | 5.0 mL | 1 mg/mL (1000 mcg/mL) |
Example calculation: For a 0.5 mg research dose from a 2 mg/mL solution — draw 0.25 mL (25 units on a U100 insulin syringe).
---
Research Dosing Protocols
The following dosing data is drawn from published clinical trial protocols. All doses listed below were used in formal research settings under investigational oversight. This information is provided for educational and scientific reference purposes only.
Standard Escalation Schedule (Trial-Based)
Novo Nordisk's Phase 2 and Phase 3 protocols used a stepwise escalation to minimize GI tolerability events (nausea, vomiting, decreased appetite):
| Week | Dose | Notes |
|---|---|---|
| 1–4 | 0.25 mg/week | Initiation dose |
| 5–8 | 0.5 mg/week | First escalation |
| 9–12 | 1.0 mg/week | Mid-range dose |
| 13–16 | 1.7 mg/week | Pre-maintenance |
| 17+ | 2.4 mg/week | Maintenance/target dose |
The 16-week escalation period in REDEFINE trials was designed to improve tolerability. Some Phase 2 protocols used a more compressed 8-week schedule (0.5 → 1.0 → 1.7 → 2.4 mg over 4 weeks each), which was associated with higher rates of GI adverse events.
Dose Tier Overview
0.5 mg/week: Entry-level research dose. Used in Phase 2 dose-finding studies; produced statistically significant weight reduction vs. placebo (~5% at 20 weeks). Minimal GI burden in trial data.
1.0 mg/week: Demonstrated dose-dependent response. Approximately 8–10% weight reduction at 20 weeks in monotherapy arms. Represents a mid-range pharmacological exposure.
1.7 mg/week: Sub-maximal dose used in combination studies. Suitable for studying near-plateau amylin receptor saturation.
2.4 mg/week: Maximum dose used in REDEFINE program. Target maintenance dose for CagriSema combination research. Highest efficacy with acceptable tolerability when reached via stepwise escalation.
> Injection frequency: All doses in published trials were administered once weekly, consistent with cagrilintide's ~7-day half-life.
---
CagriSema Combination Research Notes
CagriSema is not currently available as a standalone commercial product — it is an investigational combination being developed by Novo Nordisk. Researchers studying the combination protocol separately (cagrilintide + semaglutide administered as individual compounds) should be aware of the following:
Mechanistic Rationale
The CagriSema combination targets two independent satiety axes:
- •Semaglutide (GLP-1 receptor agonist): Enhances insulin secretion, reduces glucagon, slows gastric emptying via GLP-1R in the gut and vagus nerve
- •Cagrilintide (amylin receptor agonist): Centrally reduces meal size via area postrema/NTS signaling, slows gastric emptying via a distinct mechanism, suppresses glucagon independently
The additive weight reduction observed in trials (Phase 2: ~15.6% vs. ~5–8% for each monotherapy arm) supports the hypothesis that these pathways are complementary and do not compete for the same receptors.
Trial Combination Doses
In the REDEFINE Phase 3 program, CagriSema is administered at a fixed ratio:
- •Cagrilintide 2.4 mg + Semaglutide 2.4 mg — once-weekly subcutaneous injection
Phase 2 studies also investigated:
- •Cagrilintide 2.4 mg + Semaglutide 1.0 mg
- •Cagrilintide 1.7 mg + Semaglutide 2.4 mg
The 2.4/2.4 mg fixed combination produced the greatest weight reduction in Phase 2 dose-finding and was advanced to Phase 3.
Comparison Context
For context on adjacent GLP-1 agonist dosing protocols used in research:
Tirzepatide (a dual GIP/GLP-1 receptor agonist) offers a useful comparison case: it also achieves greater efficacy than GLP-1 monotherapy by engaging a second receptor system, analogous to how CagriSema adds amylin agonism to GLP-1 activity.
---
Storage & Stability
Lyophilized (Unreconstituted)
| Condition | Duration |
|---|---|
| 2–8°C (refrigerated) | Up to expiration date on label |
| Room temperature (≤25°C) | Up to 28 days |
| Frozen (−20°C) | Extended storage; avoid repeated freeze-thaw cycles |
Reconstituted Solution
| Condition | Duration |
|---|---|
| 2–8°C (refrigerated) | 21–28 days (BWI preserved) |
| Room temperature | 24–48 hours maximum |
| Frozen | Not recommended post-reconstitution |
Stability considerations:
- •Cagrilintide's fatty-acid acylation makes it more stable than unmodified amylin peptides, but pH and temperature excursions can still cause degradation
- •Keep reconstituted solution away from direct light — store in amber vials or wrapped in foil
- •Do not expose to repeated temperature cycling; each freeze-thaw cycle risks aggregation and loss of biological activity
- •Discard any vial showing visible particulates, cloudiness, or color change
---
Safety Considerations
The following safety profile is based on published clinical trial data. This information is provided for research context only and does not constitute medical advice.
Most Common Adverse Events (Trial Data)
In Phase 2 and Phase 3 trials, the most frequently reported adverse events were gastrointestinal in nature:
| Adverse Event | Approximate Incidence (2.4 mg/week) |
|---|---|
| Nausea | 30–40% |
| Vomiting | 15–20% |
| Decreased appetite | 25–35% |
| Constipation | 10–15% |
| Injection site reactions | 5–10% |
GI events were typically mild-to-moderate, more frequent at dose initiation and escalation steps, and diminished over time with continued administration. The stepwise escalation protocol was specifically designed to manage these events.
Notable Considerations
Hypoglycemia risk: As monotherapy, cagrilintide demonstrated low hypoglycemia risk in non-diabetic subjects, consistent with amylin's glucose-dependent glucagon suppression. In diabetic populations or with co-administration of insulin or sulfonylureas, hypoglycemia risk increases.
Calcitonin and thyroid: Amylin analogs share receptor homology with calcitonin, which raises theoretical concern for C-cell stimulation. Preclinical findings with some GLP-1 receptor agonists triggered thyroid monitoring requirements. No formal thyroid malignancy risk has been established for cagrilintide, but trials included monitoring protocols.
Cardiovascular: Phase 2 data showed neutral to potentially favorable cardiovascular effects (blood pressure reduction, lipid improvements). Long-term cardiovascular outcome trials are ongoing as part of the REDEFINE program.
Renal function: No dose adjustment was required in Phase 2 for mild-to-moderate renal impairment; limited data exist for severe impairment.
---
Summary: Cagrilintide Protocol at a Glance
| Parameter | Value |
|---|---|
| Compound class | Long-acting amylin receptor agonist |
| Receptor targets | AMYLIN1/2/3 (CalcR + RAMP complexes) |
| Dosing frequency | Once weekly (SC) |
| Dose range (trials) | 0.5 mg → 2.4 mg/week (escalating) |
| Target maintenance dose | 2.4 mg/week |
| Reconstitution solvent | Bacteriostatic water |
| Storage (reconstituted) | 2–8°C, up to 28 days |
| Key combination | CagriSema: 2.4 mg cagrilintide + 2.4 mg semaglutide |
| Mechanism | Amylin receptor agonism (central satiety + gastric emptying) |
---
Disclaimer
For Research Use Only. Not for Human Use.
This article is intended for scientific and educational purposes only. Cagrilintide is an investigational compound. It is not approved by the FDA or any regulatory authority for human use outside of authorized clinical trials. All dosing information presented here is derived from published clinical trial protocols and is provided solely for research reference. This content does not constitute medical advice, clinical guidance, or endorsement of any specific protocol. Researchers working with peptide compounds must comply with all applicable institutional, local, and federal regulations governing the use of investigational substances.